| Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status (NCT07094893) | Gruppo Oncologico del Nord-Ovest | 2026-09-15 |
| Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma (NCT07763171) | Gruppo Oncologico del Nord-Ovest | 2026-09-01 |
| Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) (NCT07485296) | Gruppo Oncologico del Nord-Ovest | 2026-01-27 |
| Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. (NCT07407465) | Gruppo Oncologico del Nord-Ovest | 2025-10-20 |
| Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. (NCT06897644) | Gruppo Oncologico del Nord-Ovest | 2025-03-27 |
| Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19. (NCT06869473) | Gruppo Oncologico del Nord-Ovest | 2025-02-20 |
| FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. (NCT06733038) | Gruppo Oncologico del Nord-Ovest | 2024-11-15 |
| Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC (NCT06578559) | Gruppo Oncologico del Nord-Ovest | 2024-07-23 |
| Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients (NCT06332079) | Gruppo Oncologico del Nord-Ovest | 2024-03-13 |
| Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease (NCT06253650) | Gruppo Oncologico del Nord-Ovest | 2024-03-01 |
| CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence (NCT06037980) | Gruppo Oncologico del Nord-Ovest | 2023-11-07 |
| Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (NCT05062889) | Gruppo Oncologico del Nord-Ovest | 2023-05-17 |
| Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery (NCT05594290) | Gruppo Oncologico del Nord-Ovest | 2022-12-07 |
| Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer (NCT04825990) | Gruppo Oncologico del Nord-Ovest | 2022-03-24 |
| Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. (NCT04564898) | Gruppo Oncologico del Nord-Ovest | 2022-01-25 |
| Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 (NCT05253846) | Gruppo Oncologico del Nord-Ovest | 2022-01-25 |
| TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (NCT04817826) | Gruppo Oncologico del Nord-Ovest | 2021-04-01 |
| Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC (NCT04681469) | Gruppo Oncologico del Nord-Ovest | 2021-02-08 |
| Tailored Sonidegib Schedule After Complete Response in BCC (NCT04806646) | Gruppo Oncologico del Nord-Ovest | 2021-01-12 |
| PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (NCT04787341) | Gruppo Oncologico del Nord-Ovest | 2020-12-15 |
| AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (NCT04513951) | Gruppo Oncologico del Nord-Ovest | 2020-04-01 |
| Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours (NCT03923842) | Gruppo Oncologico del Nord-Ovest | 2019-06-30 |
| Immunotherapy In Locally Advanced Rectal Cancer (NCT03854799) | Gruppo Oncologico del Nord-Ovest | 2019-04-01 |
| Targeting the Tumor Microenvironment in R/M SCCHN (NCT03844763) | Gruppo Oncologico del Nord-Ovest | 2019-01-07 |
| FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients (NCT03721653) | Gruppo Oncologico del Nord-Ovest | 2018-11-30 |
| Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS) (NCT03944252) | Gruppo Oncologico del Nord-Ovest | 2018-09-18 |
| NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN (NCT05802290) | Gruppo Oncologico del Nord-Ovest | 2017-11-27 |
| First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS (NCT03231722) | Gruppo Oncologico del Nord-Ovest | 2017-09-13 |